GLAXF:OTC-GSK plc (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 17.49

Change

-0.12 (-0.68)%

Market Cap

N/A

Volume

1.13K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-14 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
LLY Eli Lilly and Company

-25.58 (-3.15%)

USD 737.03B
NVO Novo Nordisk A/S

-1.59 (-1.49%)

USD 499.24B
JNJ Johnson & Johnson

-1.37 (-0.89%)

USD 380.12B
ABBV AbbVie Inc

-0.72 (-0.42%)

USD 302.34B
PFE Pfizer Inc

-0.70 (-2.62%)

USD 163.54B
BMY Bristol-Myers Squibb Company

+0.09 (+0.15%)

USD 118.65B
OGN Organon & Co

-0.30 (-1.92%)

USD 4.84B
NVS Novartis AG ADR

-0.46 (-0.44%)

N/A
GSK GlaxoSmithKline PLC ADR

-0.72 (-2.05%)

N/A
MRK Merck & Company Inc

-0.14 (-0.14%)

N/A

ETFs Containing GLAXF

DX2K:F Xtrackers - FTSE 100 Shor.. 0.00 % 0.00 %

N/A

N/A
DX2K:XETRA Xtrackers FTSE 100 Short .. 0.00 % 0.00 %

N/A

USD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 18.53% 91% A- 72% C
Dividend Return -53.43% 9% A- N/A F
Total Return -34.90% 9% A- 5% F
Trailing 12 Months  
Capital Gain 27.48% 82% B 71% C-
Dividend Return -57.47% 9% A- N/A F
Total Return -29.99% 9% A- 5% F
Trailing 5 Years  
Capital Gain -20.25% 20% F 23% F
Dividend Return -21.13% 10% F N/A F
Total Return -41.38% 10% F 9% A-
Average Annual (5 Year Horizon)  
Capital Gain -2.42% 53% F 33% F
Dividend Return 1.81% 50% F 37% F
Total Return 4.23% 85% B 68% D+
Risk Return Profile  
Volatility (Standard Deviation) 22.03% 59% D- 84% B
Risk Adjusted Return 8.20% 50% F 41% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector